Citigroup Sets PA GOODDOCTOR (01833) Price Target at HK$18 with "Buy" Rating Following Strong 2025 Earnings Beat

Stock News
03/25

Citigroup has issued a research report stating that PA GOODDOCTOR (01833) achieved revenue of 5.468 billion yuan in 2025, representing a 14% year-on-year increase, with a net profit of 380 million yuan, surging 366% compared to the previous year. The full-year revenue met expectations, while the net profit exceeded market and the bank's own forecasts by 37% and 32%, respectively. The bank currently assigns a target price of HK$18 and a "Buy" rating. During the period, the gross profit margin improved from 31.7% in 2024 to 32.4%, and the net profit margin rose from 1.7% to 6.9%. Supported by AI empowerment and enhanced efficiency management, the adjusted net profit margin increased from 3.3% to 7.6%.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10